Suranjan Roychowdhury, PhD Joins EBT Medical as Vice President of Clinical Affairs

Ex-Cogentix and AMS executive joins to lead company’s growing Clinical Research department

Boston, Massachusetts and Toronto, Ontario – February 24, 2020 – EBT Medical, Inc. (“EBT”) a venture-backed clinical-stage startup developing disruptive neuromodulation therapies for pelvic health disorders, today announced that Suranjan Roychowdhury, PhD has joined the company as Vice President of Clinical Affairs.

“We are very excited to welcome Suranjan to our growing leadership team,” said Keith R. Carlton, CEO of EBT. “Given his deep experience leading clinical organizations at two top-tier companies in pelvic health— AMS and Cogentix— as well as his experience in research and development, regulatory, and business development, we could not have asked for a better fit to our leadership team to drive worldclass evidence on our proposed first-line OAB therapy.”

“I am excited to be joining EBT and its very accomplished team,” said Dr. Roychowdhury. “EBT’s unique, noninvasive neuromodulation technology holds the promise of helping millions of patients who live with debilitating chronic diseases like OAB, who aren’t ready for a pill or surgical procedure to treat their condition. I am pleased to be a part of the effort that will bring this novel technology to patients and the clinicians who serve them.”

Suranjan is a clinical, product development, and commercialization leader with extensive business, technical and scientific experience. He has an established track record of successful ‘concept to market’ clinical development experience across a range of single-use and implantable medical devices, capital equipment, and drug-device combination products. Prior to joining EBT, he held high-level leadership positions in Clinical, Regulatory, and R&D for Cantel Medical, Cogentix Medical, and American Medical Systems. Suranjan has M.S. and Ph.D. degrees in Materials Science and Engineering from the University of Delaware, and a Bachelor’s degree in Metallurgical Engineering from the Indian Institute of Technology (BHU).

Suranjan will oversee the design and execution of EBT’s clinical strategy, starting with the company’s noninvasive neuromodulation therapy for overactive bladder (OAB). He will also drive indication expansion efforts in overall pelvic health. Lastly, given his expansive background, we expect Suranjan will play a significant role in R&D, regulatory,

About EBT Medical
EBT Medical was founded in 2014 based on scientific discoveries made at the University of Toronto with a mission to develop novel neuromodulation technologies that restore control, dignity and independence to those silently suffering from pelvic floor disorders. EBT’s first product is a clinical-grade, noninvasive neurostimulator and associated ecosystem for overactive bladder (OAB). EBT has a significant patent estate around multiple neuromodulation technologies including issued patents on the Saphenous nerve for all pelvic health indications. EBT’s management team and world-class advisory board have decades of relevant experience in pelvic health, neuromodulation, and consumer health. Learn more about EBT Medical at

About Overactive Bladder and Neuromodulation
Overactive bladder is a disabling syndrome affecting nearly 550M worldwide1. It is characterized by frequent, sudden, uncontrollable urges to void, often followed by incontinence episodes that are embarrassing and significantly impede activities of daily living. The major symptom of OAB, Urge Urinary Incontinence (UUI), is thought to be caused by over-signaling to & from the bladder and the pontine micturition center located in the brain stem. Over 50%2 of those with OAB remain undiagnosed and silently suffer, with marked increases in depression, anxiety, sleeplessness due to nocturia (waking to void), and social isolation. The economic impact of OAB in the United States was estimated at $76B including direct costs and indirect costs such as increased urinary tract infections, falls from running to the bathroom, and absenteeism3. Neuromodulation has been an established therapy for UUI since it was first approved in 1997. 

Keith R Carlton
Chief Executive Officer
[email protected]

Certain information set forth in this press release contains “forward-looking information”, including “future oriented financial information” and “financial outlook”, under applicable securities laws (collectively referred to herein as forward-looking statements). Except for statements of historical fact, information contained herein constitutes forward-looking statements. Forward-looking statements are provided to allow potential investors the opportunity to understand management’s beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment.

These statements are not guarantees of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements.

Although forward-looking statements contained in this presentation are based upon what management of EBT Medical believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. EBT Medical undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.

1 546M affected individuals in 2018. Filipetto et al.: The patient perspective on overactive bladder: a mixed-methods needs assessment. BMC Family Practice 2014 15:96.
2 Ibid.
3$76B in 2015. J Manag Care Pharm. 2014 Feb;20(2):130-40. “Economic burden of urgency urinary incontinence in the United States: a systematic review.”

Share this :

Share on facebook
Share on twitter
Share on linkedin
Share on email